| Sign In to gain access to subscriptions and/or personal tools. |
Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgeryDivision of Cardiology, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy david{at}mocini.it
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Laboratory Medicine Department, San Filippo Neri Hospital, Rome, Italy
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy david{at}mocini.it
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
The "Sapienza" University of Rome. Dipartimento di Statistica, Probabilità e Statistiche Applicate, San Filippo Neri Hospital, Rome, Italy
Division of Cardiac Surgery, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Division of Cardiology, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy
Erythropoietin (EPO) exerts a tissue-protective activity in several non-haematopoietic tissues such as heart, brain, spinal cord and muscle. We evaluated the relationship between pre-operative endogenous EPO blood levels and myocardial damage in patients undergoing cardiopulmonary bypass (CPB). Furthermore, we investigated whether pre-operative administration of a single bolus of 40,000 IU epoetin alpha (EPO
Key Words: epoetin alpha erythropoietin ischaemia myocardial reperfusion injury
Perfusion, Vol. 23, No. 3,
187-192 (2008) |
||||
) would reduce troponin I or creatine kinase isoenzyme (CK-MB) after on-pump coronary artery bypass graft (CABG) surgery. Sixty-seven patients (45 CABG, 22 valvular surgery) were enrolled. EPO was measured in the pre-surgical period and correlated to post-surgical troponin I and CK-MB peaks. Subsequently, forty patients scheduled for CABG were randomized into two groups, receiving, respectively, a) standard medical and surgical treatment (20 patients) and b) the same treatment plus 40,000 IU of EPO